The other gene edited-αβ T cell products targeting BCMA for MM treatment, CTX120, are produced using the CRISPR/Cas9 system to eliminate TCR and MHC class I, coupled with specific insertion of the CAR at the TRAC locus [44]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.